Fox Run Management’s Bionano Genomics BNGO Stock Holding History

Fox Run Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20	Closed	-$99K	–	346
2021 Q1	$99K	Buy	+20	New	+$113K	0.18%	187

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Fox Run Management's BNGO Position: Q2 2021 in Review

Fox Run Management sold out of Bionano Genomics (BNGO) in Q2 2021, closing a stake of 20 shares — an estimated $99K sold.

Fox Run Management first reported a position in BNGO in Q1 2021 and held it in 1 quarter. The position peaked at $99K in Q1 2021. 152 funds tracked by Wall St. Rank hold BNGO as of Q2 2021.

Fox Run Management reported no remaining Bionano Genomics position as of Q2 2021 after selling out during the quarter.
Fox Run Management sold 20 Bionano Genomics shares in Q2 2021, an estimated $99K.
Fox Run Management first reported a position in Bionano Genomics in Q1 2021 and held it in 1 quarter.
Fox Run Management's Bionano Genomics position peaked at $99K in Q1 2021.
152 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2021.

Based on Fox Run Management's 13F filing for Q2 2021, filed 5 Aug 2021.